Thirty years of research on the dawn phenomenon: Lessons to optimize blood glucose control in diabetes

Diabetes Care

Volumn 36, Issue 12, 2013, Pages 3860-3862

  Porcellati, Francesca ^a   Lucidi, Paola ^a   Bolli, Geremia B ^a   Fanelli, Carmine G ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; RECOMBINANT HUMAN INSULIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; BLOOD GLUCOSE MONITORING; CONTINUOUS INFUSION; DIABETES MELLITUS; EVENING DOSAGE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOLYSIS; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; BLOOD; CIRCADIAN RHYTHM; DIET; FEMALE; MALE; METABOLISM;

BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DIET; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE;

EID: 84891866264     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2088     Document Type: Note

References (22)

1. Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care 1981;4: 579-585
2. Bolli GB, Gerich JE. The "dawn phenomenon"-a common occurrence in both non-insulin-dependent and insulindependent diabetes mellitus. N Engl J Med 1984;310:746-750
3. Schmidt MI, Lin QX, Gwynne JT, Jacobs S. Fasting early morning rise in peripheral insulin: evidence of the dawn phenomenon in nondiabetes. Diabetes Care 1984; 7:32-35
4. Bolli GB, De Feo P, De Cosmo S, et al. Demonstration of a dawn phenomenon in normal human volunteers. Diabetes 1984; 33:1150-1153
5. Kruszynska YT, Home PD. Night-time metabolic changes in normal subjects in the absence of the dawn phenomenon. Diabete Metab 1988;14:437-442
6. PubMed.gov. Search results for "dawn phenomenon." Available at www.ncbi.nlm.nih.gov/pubmed/?term=dawn+phenomemon. Accessed 28 August 2013
7. Monnier L, Colette C, Dejager S, Owens D. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care 2013;36:4057-4062
8. Owens DR, Bolli GB. Beyond the era of NPH insulin-long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther 2008;10:333-349
9. Brennan JR, Gebhart SS, Blackard WG. Pump-induced insulin aggregation. A problem with the Biostator. Diabetes 1985;34: 353-359
10. Bending JJ, Pickup JC, Collins AC, Keen H. Rarity of a marked "dawn phenomenon" in diabetic subjects treated by continuous subcutaneous insulin infusion. Diabetes Care 1985;8:28-33
11. De Feo P, Perriello G, Ventura MM, et al. Studies on overnight insulin requirements and metabolic clearance rate of insulin in normal and diabetic man: relevance to the pathogenesis of the dawn phenomenon. Diabetologia 1986;29:475-480
12. Perriello G, De Feo P, Torlone E, et al. The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia 1991;34: 21-28
13. Campbell PJ, Bolli GB, Cryer PE, Gerich JE. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med 1985;312:1473-1479
14. Perriello G, De Feo P, Torlone E, et al. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 1990;33:52-59
15. Boden G, Chen X, Urbain JL. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes 1996;45:1044-1050
16. Perriello G, Pampanelli S, Del Sindaco P, et al. Evidence of increased systemic glucose production and gluconeogenesis in an early stage of NIDDM. Diabetes 1997; 46:1010-1016
17. Radziuk J, Pye S. Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour? Diabetologia 2006;49:1619-1628
18. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-269
19. Monnier L, Colette C, Sardinoux M, Baptista G, Regnier-Zerbib A, Owens D. Frequency and severity of the dawn phenomenon in type 2 diabetes: relationship to age. Diabetes Care 2012;35:2597-2599
20. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
21. Porcellati F, Lucidi P, Candeloro P, et al. Pharmacokinetics and pharmacodynamics of insulin glargine: changes in glucose and lipid metabolism after either evening or morning injection in T2DM. Diabetes 2013;62(Suppl.1): A242
22. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328